CURASEN THERAPEUTICS

curasen-therapeutics-logo

CuraSen Therapeutics is a biopharmaceutical company that develops orphan drugs to treat neurodegenerative diseases, including Parkinson's disease and Alzheimer's disease.

#SimilarOrganizations #People #Financial #Website #More

CURASEN THERAPEUTICS

Social Links:

Industry:
Biotechnology Medical Device Therapeutics

Founded:
2016-01-01

Address:
San Carlos, California, United States

Country:
United States

Website Url:
http://www.curasen.com

Total Employee:
11+

Status:
Active

Contact:
+1 650 475 2842

Email Addresses:
[email protected]

Total Funding:
72.5 M USD

Technology used in webpage:
SPF Microsoft Exchange Online Office 365 Mail Microsoft Azure DNS Google Google Cloud Google Cloud Iowa


Similar Organizations

accent-therapeutics-logo

Accent Therapeutics

Accent Therapeutics is a biopharmaceutical company.

cygnal-therapeutics-logo

Cygnal Therapeutics

Cygnal Therapeutics is a biotechnology company

emendo-biotherapeutics-logo

Emendo Biotherapeutics

Emendo Biotherapeutics is a biotechnology company

excellthera-logo

ExCellThera

ExCellThera is an advanced clinical stage biotechnology company.

libra-therapeutics-logo

Libra Therapeutics

Libra Therapeutics is a biotechnology company.

moma-therapeutics-logo

MOMA Therapeutics

MOMA Therapeutics operates as a biotechnology company.

primmune-therapeutics-logo

Primmune Therapeutics

Primmune Therapeutics is a Biotechnology company.

terray-therapeutics-logo

Terray Therapeutics

Terray Therapeutics is a biotechnology company that propels drug discovery into the information age.


Current Advisors List

patrick-enright_image

Patrick Enright Board Of directors @ CuraSen Therapeutics
Board_member

henry-skinner_image

Henry Skinner Board Of directors @ CuraSen Therapeutics
Board_member

kathleen-sereda-glaub_image

Kathleen Sereda Glaub Board Member @ CuraSen Therapeutics
Board_member

liam-ratcliffe_image

Liam Ratcliffe Board Of directors @ CuraSen Therapeutics
Board_member

Current Employees Featured

peter-g-butera_image

Peter G. Butera
Peter G. Butera Senior Vice President, Operations @ CuraSen Therapeutics
Senior Vice President, Operations
2019-08-01

anthony-p-ford_image

Anthony P. Ford
Anthony P. Ford Chief Executive Officer @ CuraSen Therapeutics
Chief Executive Officer

gabriel-vargas_image

Gabriel Vargas
Gabriel Vargas Chief Medical Officer @ CuraSen Therapeutics
Chief Medical Officer

robert-booth_image

Robert Booth
Robert Booth Founder @ CuraSen Therapeutics
Founder

mehrdad-shamloo_image

Mehrdad Shamloo
Mehrdad Shamloo Founder @ CuraSen Therapeutics
Founder

wei-chen_image

Wei Chen
Wei Chen Vice President, Head of Chemistry @ CuraSen Therapeutics
Vice President, Head of Chemistry

kathleen-sereda-glaub_image

Kathleen Sereda Glaub
Kathleen Sereda Glaub Co-Founder @ CuraSen Therapeutics
Co-Founder

Founder


anthony-p-ford_image

Anthony P. Ford

kathleen-sereda-glaub_image

Kathleen Sereda Glaub

mehrdad-shamloo_image

Mehrdad Shamloo

robert-booth_image

Robert Booth

Investors List

pappas-capital_image

Pappas Capital

Pappas Capital investment in Series A - CuraSen Therapeutics

chiesi-ventures_image

Chiesi Ventures

Chiesi Ventures investment in Series A - CuraSen Therapeutics

johnson-johnson-innovation-jjdc_image

Johnson & Johnson Innovation โ€“ JJDC

Johnson & Johnson Innovation โ€“ JJDC investment in Series A - CuraSen Therapeutics

tekla-capital-management_image

Tekla Capital Management

Tekla Capital Management investment in Series A - CuraSen Therapeutics

new-leaf-venture-partners_image

New Leaf Venture Partners

New Leaf Venture Partners investment in Series A - CuraSen Therapeutics

longitude-capital_image

Longitude Capital

Longitude Capital investment in Series A - CuraSen Therapeutics

alta-partners_image

Alta Partners

Alta Partners investment in Series A - CuraSen Therapeutics

Official Site Inspections

http://www.curasen.com Semrush global rank: 8.64 M Semrush visits lastest month: 274

  • Host name: 95.6.226.35.bc.googleusercontent.com
  • IP address: 35.226.6.95
  • Location: United States
  • Latitude: 38.6583
  • Longitude: -77.2481
  • Timezone: America/New_York

Loading ...

More informations about "CuraSen Therapeutics"

About - CuraSen

CuraSen Therapeutics, Inc. is a privately funded biopharmaceutical company pursuing development of novel treatments for psychiatric and โ€ฆSee details»

CuraSen - 2025 Company Profile, Funding & Competitors - Tracxn

CuraSen is a series B company based in San Mateo (United States), founded in 2013 by Kathleen Sereda Glaub, Anthony Ford, Mehrdad Shamloo and Robert Booth. It operates as a Provider โ€ฆSee details»

CuraSen Therapeutics, Inc. - Drug pipelines, Patents, Clinical trials ...

Explore CuraSen Therapeutics, Inc. with its drug pipeline, therapeutic area, technology platform, 8 clinical trials, 18 news, and 3 literature, Disease Domain:Nervous ...See details»

CuraSen Therapeutics - Pappas Capital

CuraSen Therapeutics is focused on the discovery and development of therapies to treat neurodegenerative diseases, including Parkinsonโ€™s Disease, Alzheimerโ€™s Disease and less โ€ฆSee details»

CuraSen Therapeutics, Inc. - LinkedIn

CuraSen Therapeutics, Inc. is a privately funded biopharmaceutical company pursuing development of novel treatments for neurodegenerative diseases, including Parkinsonโ€™s โ€ฆSee details»

CuraSen Therapeutics: Revenue, Worth, Valuation & Competitors โ€ฆ

CuraSen Therapeutics is a Biotech related company founded in 2017 and based in San Mateo with an estimated revenue of $3.3M, and 21 employees. It has 10 competitors including โ€ฆSee details»

CuraSen 2025 Company Profile: Valuation, Funding & Investors

Information on valuation, funding, cap tables, investors, and executives for CuraSen. Use the PitchBook Platform to explore the full profile.See details»

Home | CuraSen

Think, Again© 2025 by CuraSen Therapeutics, Inc.See details»

CuraSen Therapeutics - Crunchbase Company Profile & Funding

CuraSen Therapeutics is a biopharmaceutical company that develops orphan drugs to treat neurodegenerative diseases, including Parkinson's disease, and Alzheimer's disease.See details»

CuraSen Therapeutics Appoints Kathleen Sereda Glaub as CEO

Oct 20, 2024 The appointment of Kathleen Sereda Glaub as CEO brings a wealth of strategic and leadership experience, positioning CuraSen for success in advancing its clinical programs. โ€ฆSee details»

CuraSen Therapeutics Appoints Kathleen Sereda Glaub Chief

Oct 15, 2024 Expands Adrenergic Pipeline to Address Neurogenic Orthostatic Hypotension and Major Depressive Disorder in Older Adults SAN CARLOS, Calif.-- (BUSINESS WIRE)- โ€ฆSee details»

CuraSen Therapeutics - News, Locations, Executives and โ€ฆ

Usearch discovered 1 location for CuraSen Therapeutics including locations in San Carlos · California. CuraSen Therapeutics is headquartered in 930 Brittan Ave. Usearch has identified โ€ฆSee details»

Curasen Therapeutics Inc. | Alzheimer's Drug Discovery Foundation

Sep 1, 2023 At CuraSen, we contend that these failures to treat complex brain diseases derive from well-intentioned, but misplaced focus on non-causal pathologic substrates, single genes, โ€ฆSee details»

Leadership - CuraSen

Prior to CuraSen, Dr. Ford co-founded Afferent Pharmaceuticals, and as chief scientific officer led the discovery and development of first-in-class P2X3 antagonists, including AF-219/MK-7264 โ€ฆSee details»

CuraSen - VentureRadar

"CuraSen Therapeutics, Inc. is developing drugs targeting a novel mechanism in the brain to restore function, improve symptoms and modify disease in a range of neurodegenerative โ€ฆSee details»

CuraSen - 2025 Funding Rounds & List of Investors - Tracxn

Jun 21, 2025 CuraSen has raised a total funding of $59.8M over 3 rounds from 7 investors. Investors include Alta Partners, New Leaf Venture Partners and 5 others. Their latest funding โ€ฆSee details»

Pipeline - CuraSen

Pipeline© 2025 by CuraSen Therapeutics, Inc.See details»

CuraCN - Drug Targets, Indications, Patents - Synapse

CuraCN: a ฮฒ2-adrenergic receptor agonists Drug, Initially developed by CuraSen Therapeutics, Inc., Now, its global highest R&D status is Phase 2, Mechanism: ฮฒ2-adrenergic receptor โ€ฆSee details»

CuraSen Therapeutics, Inc. โ€“ Funding, Valuation, Investors, News

Oct 16, 2023 CuraSen Therapeutics, Inc. is a privately funded biopharmaceutical company pursuing development of novel treatments for neurodegenerative diseases, including โ€ฆSee details»

Science - CuraSen

CuraSenโ€™s approach is focused on restoring the lost adrenergic impact of adequate noradrenaline stimulus by directly activating specific targets, such as the ฮฒ2 and ฮฑ1A adrenoceptors, for โ€ฆSee details»

linkstock.net © 2022. All rights reserved